APA (7th ed.) Citation

Chen, H., Wang, I., Tsai, Y., Lee, Y., Chen, C., Chiang, C., & Cheng, H. (2025). Superior benefits of sodium‐glucose co‐transporter‐2 inhibitors compared with dipeptidyl peptidase‐4 inhibitors for diabetic kidney disease: A cohort study. Diabetes, obesity & metabolism, 27(1), 174-183. https://doi.org/10.1111/dom.15998

Chicago Style (17th ed.) Citation

Chen, Hsiao‐Ling, I‐Ting Wang, Yi‐Wen Tsai, Yu‐Hsuan Lee, Chen‐Huan Chen, Chern‐En Chiang, and Hao‐Min Cheng. "Superior Benefits of Sodium‐glucose Co‐transporter‐2 Inhibitors Compared with Dipeptidyl Peptidase‐4 Inhibitors for Diabetic Kidney Disease: A Cohort Study." Diabetes, Obesity & Metabolism 27, no. 1 (2025): 174-183. https://doi.org/10.1111/dom.15998.

MLA (9th ed.) Citation

Chen, Hsiao‐Ling, et al. "Superior Benefits of Sodium‐glucose Co‐transporter‐2 Inhibitors Compared with Dipeptidyl Peptidase‐4 Inhibitors for Diabetic Kidney Disease: A Cohort Study." Diabetes, Obesity & Metabolism, vol. 27, no. 1, 2025, pp. 174-183, https://doi.org/10.1111/dom.15998.